Should healthy people get a whole-body MRI scan? The evidence, so far

Whole-body MRI marketed to healthy people as an early-warning test does far more flagging than finding. In a 2026 multicentre study of 327 asymptomatic adults scanned as part of a preventive programme, 138 of them — 42.2% — had at least one potentially cancer-relevant finding, while just three people, 0.9%, actually turned out to have cancer [s1]. The gap between those two numbers is the whole story of the technology, and the reason no completed evidence review yet says it does more good than harm.

What a single scan turned up

The study collected radiology reports from 327 adults (213 men and 114 women, median age 52) scanned at four centres, and had subspecialist radiologists grade findings using ONCO-RADS, a standard scale for oncologically relevant findings [s1]. It counted 237 findings rated ONCO-RADS 3 or higher — the categories that call for further work-up — across those 138 individuals [s1].

Almost all of that was uncertainty rather than disease. Of the flagged findings, 232 (97.9%) were ONCO-RADS 3, the "indeterminate" grade; only three (1.3%) were ONCO-RADS 4 and two (0.8%) were ONCO-RADS 5, the grades that strongly suggest cancer [s1]. When the indeterminate findings were chased down, three malignancies were confirmed — a prostate cancer, a renal cell carcinoma and an appendiceal carcinoma — a cancer prevalence of 0.9% in the group [s1].

So for every person the scan correctly identified with cancer, dozens more were told they had something that warranted a closer look and, in the end, did not. That is not a malfunction. It is what a very sensitive test does when it is aimed at a population where the disease it is hunting is rare.

The incidentaloma problem is general, and quantified

Whole-body imaging is a machine for producing incidental findings — "incidentalomas" — and the scale of the problem was mapped before the commercial scans took off. A 2018 BMJ umbrella review pooled 20 systematic reviews covering 240 primary studies and found that incidental findings turned up in more than a third of images for several common tests, including cardiac MRI [s2].

The follow-up question — how often an incidental finding is actually cancer — has an uncomfortable answer: it depends entirely on the organ, and it is usually low. In that review the chance that an incidental finding was malignant was under 5% for the brain, parotid and adrenal gland; between 10% and 20% for extra-colonic, prostatic and colonic findings; around a quarter for renal, thyroid and ovarian findings; and highest, at 42% (95% CI 31–54%), for the breast [s2]. Each of those chased findings can mean more scans, a biopsy, weeks of worry, and occasionally a complication from the work-up itself — harms that fall on people who were well when they walked in.

Why the evidence verdict is still "not proven"

The claim a scan company makes is not really about findings; it is that finding things early makes people live longer or better. That is a claim about outcomes, and it has not been tested the way a screening test is supposed to be. As of August 2026, the Cochrane collaboration had only registered a protocol to evaluate the benefits and harms of whole-body MRI or CT screening in asymptomatic adults — the review itself is yet to be done [s3]. A protocol is a statement of intent to weigh the evidence, which means no completed systematic synthesis showing a mortality or morbidity benefit currently exists [s3].

That absence is the crux. Established screening programmes — for a specific cancer, in a defined population — earn their place by showing in trials that they cut deaths without doing net harm. Whole-body MRI is being sold to everyone, for everything, ahead of that evidence. A CMAJ editorial in early 2026, prompted by moves to let people privately buy diagnostic scans without a referral, made the point bluntly in its title: let the buyer beware [s4]. Its concern was precisely that direct-to-consumer testing outruns the evidence that it helps [s4].

How to read the pitch

The marketing frames a whole-body scan as pure information, and more information as obviously good. The data reframe it: a scan of a healthy person is far more likely to start a cascade of follow-up than to catch a cancer that matters [s1] [s2], and the case that catching things this way extends life has not been made [s3]. The same logic — that screening a low-risk population mostly generates findings to chase — runs through the debates over screening the carotid arteries in people without symptoms and the broader marketplace of direct-to-consumer "biological age" and longevity tests.

This is not medical advice, and it is not a claim that a scan never helps anyone; a small number of real cancers were found [s1]. It is the state of the evidence: for a person with no symptoms, a whole-body MRI is a test whose harms are documented and whose benefits, so far, are not.